HZNP - Horizon Therapeutics confirms FTC Second Request in Amgen deal

• Horizon Therapeutics ( NASDAQ: HZNP ) and Amgen ( NASDAQ: AMGN ) confirmed the companies received a "Second Request" from the Federal Trade Commission in regards to the planned almost $28 billion acquisition of the rare-disease focused company. Horizon fell 0.8% in after hours trading.
• Horizon ( HZNP ) and Amgen ( AMGN ) each received a request for additional information and documents from the FTC on Monday, according to an 8-K filing . Both parties intend to promptly respond to the second request and to continue to work cooperatively with the FTC in its review.
• Amgen ( AMGN ) agreed to  Horizon Therapeutics for $116.50 per share in cash last month, valuing the Ireland-based biotech at nearly $27.8 billion.
• The FTC request comes as Sen. Elizabeth Warren (D-MA) on Wednesday wrote a letter to the the antitrust regulator about her concerns with the transaction.
• Amgen on Tuesday after the close reported Q4 non-GAAP EPS of $4.09 in-line, r evenue of $6.8B beat by $30 million.

For further details see: